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INTRODUCTION
Lung and colorectal cancer are two of the 
most common cancers seen in UK primary 
care. Colorectal cancer is the second most 
commonly diagnosed cancer in the UK, 
with almost 40 000 new cases per year 
documented in 2009.1 Lung cancer deaths 
in England and Wales represent 22% of 
the total mortality from cancer.2 Patients 
in the UK have been reported to present 
later and do worse than in other countries,3 
raising the issues of early identification and 
referral in primary care, prompt diagnosis, 
and effective treatment. However, most 
symptoms that may indicate cancer are 
common in primary care and are associated 
with a very low cancer risk. Referrals based 
on these symptoms can lead to unnecessary 
anxiety and investigations for patients at low 
risk, and unnecessary use of secondary 
care services.
One way of expressing a patient’s risk 
of cancer is to use a positive predictive 
value (PPV), which is the proportion of 
people with a particular diagnostic indicator 
who go on to develop cancer.4 There is a 
lack of evidence for the predictive values 
of lung or colorectal cancer symptoms, 
signs, and test results derived from high-
quality, prospective primary care cohorts.5–7 
In consulting populations the proportion 
with cancer is lower in primary care than 
in secondary care, and consequently 
the PPVs for this population are lower. 
Recent systematic reviews have identified 
few symptoms, signs, and test results in 
primary care that have a PPV of above 5%,4,8 
meaning that many have a relatively low risk 
of being cancer-related.
Clinical prediction rules (CPRs), derived 
from prospective data collection and 
consisting of the combination of symptoms, 
signs, and test results most strongly 
associated with cancer risk, may be the most 
robust and reliable way to inform decisions 
regarding further investigations and onward 
referral. Existing CPRs for assessing cancer 
risk have often been developed in secondary 
care populations,9 meaning they may be 
less accurate in primary care, and others10,11 
have been derived using only routinely 
collected data, which may not provide valid, 
standardised information in the way that 
a study designed specifically to collect 
information on diagnostic indicators would 
do. A large, prospective primary care-based 
cohort study (CANcer DIagnosis Decision 
rules, CANDID) has therefore been designed 
to derive prediction rules to support the 
early diagnosis of lung cancer and colorectal 
cancer in primary care. This Delphi study 
represents the first phase of this project, 
and aims to obtain consensus regarding 
potential diagnostic indicators that are 
important for assessing risk of lung and 
colorectal cancer in primary care consulters 
presenting with symptoms of possible 
oncological significance, with a particular 
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Abstract
Background
Patients with lung or colorectal cancer often 
present late and have a poor prognosis. 
Identifying diagnostic indicators to optimally 
assess the risk of these cancers in primary 
care would support early identification and 
timely referral for patients at increased risk.
Aim
To obtain consensus regarding potential 
diagnostic indicators that are important for 
assessing the risk of lung or colorectal cancer 
in primary care consulters presenting with lung 
or abdominal symptoms.
Design and setting
A Delphi study was conducted with 
28 participants from primary and secondary 
care and academic settings in the UK and 
Europe.
Method
Indicators were obtained from systematic 
reviews, recent primary studies and 
consultation with experts prior to the Delphi 
study being conducted. Over three rounds, 
participants rated each diagnostic indicator 
in terms of its importance, ranked them in 
order of importance, and rated each item as 
crucial or not crucial to assess during a GP 
consultation.
Results
The final round resulted in 25 items remaining 
for each type of cancer, including established 
cancer symptoms such as rectal bleeding 
for colorectal cancer and haemoptysis for 
lung cancer, but also less frequently used 
indicators such as patients’ concerns about 
cancer.
Conclusion
This study highlights the items clinicians feel 
would be most crucial to include in the clinical 
assessment of primary care patients, a number 
of which have rarely been noted in the previous 
literature. Their importance in assessing the 
risk of lung or colorectal cancer will be tested 
as part of a large prospective cohort study 
(CANDID). 
Keywords
Delphi technique; neoplasms; primary health 
care; referral and consultation.
emphasis on factors not already supported 
by evidence from previous research.
METHOD
A modified Delphi study12 was designed 
to achieve consensus regarding key 
diagnostic indicators in the identification 
of primary care patients at risk of lung or 
colorectal cancer. The Delphi is described 
as modified because participants were 
presented with a list of items to consider, 
rather than generating their own items,12 
although there was an option to do this 
within the study. The Delphi process was 
anonymised, with panel members unaware 
of the identity of other members, and 
responses kept anonymous.
Identification of Delphi panel members
A panel of national and international cancer 
experts, researchers, and clinicians from 
primary and secondary care were invited 
to participate. Participants were identified 
through the West Midlands North primary 
care research network, as authors of 
relevant research publications identified 
from a scoping search, or via personal 
networks of the CANDID study team. 
Seventy-three potential participants were 
initially identified, with the aim to recruit 
approximately 20 panel members. There 
are no set guidelines for deciding on the 
optimum number of Delphi participants as 
this is likely to change depending on the 
purpose of the Delphi.13
Design of the Delphi study
All study materials were sent to participants 
via email. Participants were informed that 
their responses would be anonymised. 
The Delphi rounds were constructed 
using web-based survey software (Survey 
Monkey), which participants accessed 
via a weblink included in the email. The 
study was conducted between August and 
November 2012.
An overview of data collection throughout 
the study can be found in Figure 1. The first 
round of the Delphi contained the consent 
form, and participants could only access 
the survey if they consented to take part. 
Participants could also choose whether 
they wanted to answer questions relating 
to both types of cancer or only lung or 
colorectal cancer. Items to be included in 
the first round of the Delphi were identified 
from a scoping search of the literature 
to locate previously conducted systematic 
reviews and key primary studies that 
had identified factors predictive of lung 
or colorectal cancer in primary care (for 
example). 4,8,14,15 Other items were identified 
by members of the study team and through 
discussion with expert clinicians.
Round 1 involved participants rating 
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How this fits in
It is known that patients with lung or 
colorectal cancer often present late and 
have a poor prognosis. Developing clinical 
prediction rules for primary care may help 
ensure prompt and appropriate referral. 
This Delphi study has generated a list of 
diagnostic indicators that primary care 
clinicians feel are crucial to assess in a 
consultation with a patient presenting with 
symptoms that may be indicative of lung 
or colorectal cancer. These items will 
be tested as part of a large, prospective 
primary care-based cohort study, which 
will help identify the most important 
factors for clinicians to focus on when 
presented with a patient with lung or 
colorectal  symptoms.
Experts identified via 
research and personal 
contacts (n = 73)
Invited to participate via 
email:
Consent Y/N
If Y, sent access to Round 1
Round 1 (n = 28): 
Panel members rate 
importance of each indicator 
on a 1–5 scale
Items with mean rating <3 
removed
Round 2 (n = 19):
 
Panels members rate each 
indicator and then rank them:
Cut point for removing items 
discussed with clinician 
Round 3 (n = 19):
 
Panel members rate each 
indicator as crucial or not for
assessment in primary care 
& can re-introduce removed 
items if crucial
Non-response: n = 43
Declined: n = 2
CRC
RF: 5 removed; 4 added
Sy: 1 removed, 3 added
Si: 0 removed, 1 added
T: 2 removed, 2 added
LC
RF: 1 removed, 5 added
Sy: 0 removed, 0 added
Si: 0 removed, 1 added
T: 0 removed, 2 added
CRC
RF: 6 removed
Sy: 11 removed
Si: 5 removed
T: 4 removed
LC
RF: 7 removed
Sy: 5 removed
Si: 1 removed
T: 6 removed
CRC
RF: 9 included
Sy: 9 included
Si: 5 included
T: 2 included
LC
RF: 9 included
Sy: 7 included
Si: 8 included
T: 1 included
Figure 1. Flowchart of how information was 
collected over the three Delphi rounds.  
CRC = colorectal cancer. LC = lung cancer.  
RF = risk factor. Sy = symptom. Si = sign. T = test.
the identified diagnostic indicators on a 
5-point Likert scale, ranging from ‘very 
unimportant’ to ‘very important’. The 
indicators were split into ‘key risk factors’, 
‘symptoms’, ‘signs’ and ‘tests’ for lung and 
colorectal cancer. Participants could also 
add up to three additional indicators that 
they felt were missing from the current 
lists, and were asked to give a reason 
why they thought that item was important. 
Participants were also asked to provide 
information on their occupation (clinical or 
non-clinical) and the number of years of 
experience they had, to allow a description 
of the key characteristics of the panel. Any 
indicators which received a mean score of 
<3.0 were removed in the second round, 
but all new indicators were included. The 
cut-off point of 3.0 was set to include most 
items deemed important at this early stage.
Round 2 involved participants ranking 
each of the indicators in terms of how 
important they felt they were, with a score 
of 1 given to the most important indicator 
and the highest number to the least 
important indicator in each list. Summated 
scores generated a ranking within each 
list of key risk factors, symptoms, signs, 
and tests. The number of indicators to take 
forward to the final round was decided by 
the study team through discussions with 
a GP, who provided independent clinical 
input when deciding on the optimal cut-
off for removing indicators from each 
section. To allow final decisions regarding 
items that should be maintained in the 
clinical assessment, participants in the final 
round were asked which of the remaining 
indicators were crucial or not crucial to 
assess in a 10-minute GP consultation 
with patients presenting with either lung 
or abdominal symptoms suggestive of 
cancer. Participants could reintroduce a 
limited number of crucial items that had 
been removed over the previous rounds, 
providing a reason for reintroduction of the 
item.
The rounds were sent out to participants 
every 4 weeks, with a reminder email being 
sent out 2 weeks after the initial email. 
All participants were sent an anonymised 
summary feedback report at the end 
of every round to inform them of study 
progress.
RESULTS
Characteristics of the Delphi panel
Of the 73 people originally invited to 
participate, 28 responded to round 1, 19 to 
round 2 and 19 to round 3. The participants 
described themselves mostly as GPs 
working in a clinical capacity (n = 25); two 
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Table 1. Inclusion and exclusion of diagnostic indicators at each 
Delphi round for colorectal cancer
  Round 1 Round 2  
  (mean score (mean rank Round 3 
Diagnostic indicator for importance) score) (crucial)
Key risk factor
Familial polyposis colia 4.92 2.44 Y
First-degree relative with colorectal cancer <50 yearsa 4.85 3.61 Y
Agea  4.54 3.17 Y
More than 10 polypsa 4.38 6.67 Y
First-degree relative with polyps <50 yearsa 4.27 5.94 Y
Second attendance with the same symptoma 4.23 9.28 Y
Inflammatory bowel diseasea 4.15 6.72 Y
Benign polyps  3.73 10.28 Nb
Smoking status  3.35 10.83 Nb
First-degree relative with other type of cancer 3.42 11.89b 
History of endometrial cancer 3.23 12.56b 
Last consultation with a GP >6 months ago 3.15 13.56b 
Alcohol intake  3.00 13.78b 
Socioeconomic statusb 2.92b
Ethnicityb  2.88b  
Diabetes mellitusb  2.73b 
Sexb  2.65b  
Occupational historyb 2.46b  
Progression of symptomsa,c  5.33 Y
Patient thinks they have colorectal cancera,c  10.94 Y
Last consultation with a GP >5 years agoc  11.00 
Patient attends with an adult family memberc  15.00 
Symptom  
Rectal bleeding: blood mixed with stoola 4.73 1.88 Y
Bowel symptoms: change in bowel habita 4.73 3.24 Y
Unintentional loss of weight reported by patienta 4.73 4.82 Y
Rectal bleeding: typea,d 4.50 4.06 Y
Symptom durationa,e  4.46 8.35 Y
Bowel symptoms: tenesmusa 4.08 8.76 Y
Bowel symptoms: urgency 3.88 9.71 Nb
Bowel symptoms: incomplete emptyinga 3.88 9.29 Y
Bowel symptoms: diarrhoeaa 3.81 8.24 Y
Fatigue  3.77 15.35b 
Loss of appetite  3.73 13.35b 
Abdominal pain  3.69 11.24b 
Bowel symptoms: nocturnal symptoms 3.62 11.47b 
Bowel symptoms: constipation 3.42 14.94b 
Distension  3.42 14.88b 
Discomfort  3.27 16.65b 
Peri-anal symptoms 3.23 14.47b 
Bloating  3.12 16.53b 
Nauseab  2.88b  
Jaundicea,c   8.24 Y
Mucus in stoolc   17.12b 
Wet windc   18.41b 
… continued
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described themselves as non-clinical, and 
one as a specialist. Across the panel there 
was a mean of 22.7 years of experience 
(range 5–42 years).
Results of round 1
The results of each round are presented in 
Table 1 and Table 2 for colorectal cancer 
and lung cancer, respectively, which also 
show which items were removed and added. 
In round 1, few items were removed for 
either cancer as almost all items received 
a mean score of ≥3.0, and a number of 
items were added. Some of these added 
items were specific to the type of cancer, 
such as melaena as a sign for colorectal 
cancer and Horner’s syndrome as a sign 
for lung cancer. Others were more generic, 
including jaundice and patients’ concerns 
regarding their symptoms for either type 
of cancer.
Results of round 2
Based on the summated rank scores 
described in the Method section, abnormal 
chest X-ray, smoking status, and 
haemoptysis were ranked most highly for 
lung cancer and iron deficiency anaemia, 
blood mixed with stool and rectal mass 
ranked most highly for colorectal cancer. 
Based on the importance given to each 
item, the number of items in each section 
(risk factors, symptoms, signs, and tests) 
was reduced by approximately 50%, 
resulting in a total number of 29 potential 
diagnostic indicators for colorectal cancer 
and 28 for lung cancer (Tables 1 and 2). The 
rank scores given to the items were very 
similar across the items for the second 
round, meaning that it was difficult to judge 
where to place a cut-off based on the rank 
scores alone.
Results of round 3
Similar to round 1, few items were removed 
for either type of cancer in this final round, 
with nearly all indicators being regarded 
as crucial. Participants could reintroduce 
previously removed items, but as none of 
these were suggested for reinclusion more 
than once, no items were re-entered. The 
final items for lung cancer included nine 
risk factors, seven symptoms, eight signs, 
and one test, while the final list of items for 
colorectal cancer was made up of nine risk 
factors, nine symptoms, five signs, and two 
tests (Figure 1). 
DISCUSSION
Summary
This Delphi study generated consensus 
among cancer experts and primary 
care clinicians regarding the diagnostic 
indicators that are most important to 
assess during a GP consultation to more 
reliably estimate a patient’s risk of lung or 
colorectal cancer. The study identified a 
list of 25 potential indicators each for lung 
cancer and colorectal cancer, which will 
provide a guide to the design of web-based 
data collection forms to be completed by 
GPs participating in the main CANDID 
study.
Strengths and limitations
As this study included a mostly primary 
care-based panel, the authors are 
confident that the results reflect what 
GPs perceive as important in everyday 
clinical practice. This is a strength as 
the CPRs will be designed and tested 
in a primary care-based study. Limited 
data collection on the characteristics of 
participants means that a full assessment 
concerning generalisability cannot be 
made. The consensus represented by the 
Table 1 continued. Inclusion and exclusion of diagnostic indicators at 
each Delphi round for colorectal cancer
  Round 1 Round 2  
  (mean score (mean rank Round 3 
Diagnostic indicator for importance) score) (crucial)
Sign 
Rectal massa  4.96 1.88 Y
Abdominal massa  4.85 3.12 Y
Cachexiaa  4.81 4.53 Y
Objective loss of weighta 4.65 4.59 Y
Rectal examination: blood on glovea 4.27 5.29 Y
Ascites  4.54 6.00b 
Hepatomegaly  4.31 6.12b 
Pale conjunctivae  3.73 8.29b 
Lymphadenopathy  3.73 7.76b 
Melaenac  7.41b 
Test 
Iron deficiency anaemiaa 4.77 1.12 Y
Anaemia  4.15 2.94 Nb
Positive faecal occult blood testa 3.96 3.53 Y
Raised erythrocyte sedimentation rate 3.73 4.18b 
Screened for colorectal cancer in the last 2 years 3.54 4.76b 
High white cell countb 2.54b  
Raised glucose levelb 2.35b  
Disturbed liver function testsc  5.06b 
Hypercalcaemiac   6.41b 
aIncluded in round 3. bExcluded in round 2. cAdded by participants in round 1. dRefers to characteristics of the 
rectal bleeding experienced (for example, dark versus bright red blood, whether the blood was noticed in the 
toilet pan or on the toilet paper. eRefers to whether the symptom was present for a long period of time as 
opposed to only a short period.
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varied clinical experience and academic 
knowledge of the panel is supported by the 
literature and also includes novel items that 
may potentially lead to an improvement in 
the early identification of cancer.
Although the items were initially chosen 
from the published literature, further 
suggestions were made by the study team 
members and Delphi panel members, 
and the choice of cut-offs for each round 
was, although a priori defined, also based 
on subjective clinical judgement. The use 
of an independent GP to provide input 
regarding the cut points after round 2 had 
the advantage of weighing towards use in 
practice, although this may have introduced 
subjectivity. The final round therefore 
allowed reintroduction of crucial items and 
consensus regarding the final outcome.
Comparison with existing literature
Consensus was reached on the classic 
alarm symptoms by which lung and 
colorectal cancer present, such as 
haemoptysis and rectal bleeding, although 
the number of acknowledged symptoms 
highlights the vagueness and variety of 
clinical presentations. Some of the crucial 
symptoms that were eventually decided 
on were subtypes of classic symptoms 
(for example, change in bowel habit) into 
more specific types (for example, diarrhoea 
as opposed to constipation), and may 
reflect clinical experience concerning the 
incidence of the more generic symptoms 
in primary care populations and their low 
predictive value for cancer. These findings 
are consistent with results from other 
primary care-based studies.8,10 Patients 
who present with classic alarm symptoms 
may have a lower risk of mortality than 
those who do not,16 possibly because these 
symptoms are more easily recognisable 
as potential cancer symptoms. There may 
be some inconsistency with patients’ ideas 
concerning key symptoms, with one study 
of symptoms for colorectal cancer17 finding 
rectal bleeding, change in bowel habit, 
and weight loss being commonly reported 
symptoms, along with pain, fatigue, and 
‘general indisposition’ or feeling of being 
unwell. Pain and fatigue have been reported 
as warning signs for cancer,18 but with very 
low PPVs.
Well-known cancer-specific risk factors 
were classified by the panel as crucial 
(for example, familial polyposis coli for 
colorectal cancer and chronic obstructive 
pulmonary disease for lung cancer). With 
more generic risk factors, some appeared 
to be judged as crucial for both cancers 
(for example, age), others were seen as 
Table 2. Inclusion and exclusion of diagnostic indicators at each 
Delphi round for lung cancer
 Round 1 Round 2  
 (mean score for (mean rank Round 3 
Diagnostic indicator importance) score) (crucial)
Key risk factor
Smoking statusa 5.00 1.13 Y
Occupational exposurea 4.54 4.50 Y
Agea 4.33 3.31 Y
Second attendance with the same symptoma 4.25 8.25 Y
History of chronic obstructive pulmonary diseasea 4.13 6.81 Y
Second-hand smoke exposurea 4.04 7.00 Y
Socioeconomic status 3.71 7.19 Nb
Family history (first-degree relative)a 3.58 9.56 Y
Last consultation with a GP >6 months ago 3.46 12.88b 
History of idiopathic pulmonary fibrosis 3.42 12.75b 
History of tuberculosis 3.33 13.81b 
Sex 3.25 11.19b 
Alcohol intake 3.17 11.75b 
Ethnicityb 2.79b 
Last consultation with a GP >5 years agoc  10.38 Nb
Patient thinks they may have lung cancera,c  11.13 Y
Patient attends with an adult family memberc  15.75b 
Localisation of painc  12.63b 
Reduced exercise tolerancea,c   Y
Symptom
Haemoptysisa 4.96 1.25 Y
Unintentional loss of weight reported by patienta 4.79 4.44 Y
Symptom durationa,d 4.25 6.19 Y
Cougha 4.17 3.00 Y
Hoarsenessa 4.13 6.06 Y
Dyspnoeaa 4.00 4.38 Y
Chest paina 3.79 6.69 Y
Bone pain 3.92 9.88b 
Loss of appetite 3.88 7.88b 
Back pain 3.88 10.56b 
Fatigue 3.88 8.81b 
Shoulder pain 3.75 8.88b 
Sign
Cachexiaa 4.71 3.94 Y
Pleural massa 4.67  
Pleural effusiona 4.67 3.69 Y
Superior vena cava obstructiona 4.58 3.31 Y
Objective weight lossa 4.54 4.5 Y
Lymphadenopathya 4.25 5.94 Y
Stridora 4.21 6.00 Y
Finger clubbing 4.00 7.31b 
Horner's syndromea,c  6.50 Y
Test
Abnormal chest X-raya 4.79 1.06 Y
Abnormal sputum cytology 4.13 3.75 Nb
Anaemia 3.71 3.69 Nb
Raised erythrocyte sedimentation rate 3.75 4.63b 
Raised C-reactive protein 3.5 5.56b  
Abnormal spirometry 3.33 6.06b 
Thrombocytosis 3.25 7.31b 
Hypercalcaemiac  6.81b 
Disturbed liver function testsc  6.13b 
aIncluded in round 3. bExcluded in round 2. cAdded by participants in round 1. dRefers to whether the symptom 
was present for a long period of time as opposed to only a short period.
crucial for one cancer but not the other (for 
example, smoking for lung cancer only) 
and others were not judged to be crucial 
for either type of cancer (for example, 
socioeconomic status). This is likely to be 
reflective of the make-up of the panel who 
were mostly GPs with extended clinical 
experience. A qualitative study of GPs19 
found this experience to be a key factor in 
judging the possibility of cancer in a patient, 
and also highlighted the importance of 
interpersonal awareness and how subtle 
changes in the way a patient talks or 
behaves may be indicative of a more serious 
condition.
Symptom duration was present in 
the first round of the Delphi as an aid 
to judging cancer probability, although 
this may represent a high probability of 
cancer if the duration is short (6 weeks 
for example) or a low probability if it is 
long (years). It has been noted that time 
as a diagnostic tool should be used when 
the benefits of the delay outweigh any 
potential harm to the patient,20 and that 
it is useful when confronted with vague, 
common symptoms which characterise 
many presentations of possible cancer. The 
importance of ‘second attendance with the 
same symptom’ for lung and colorectal 
cancer and the introduction by participants 
of ‘progression of symptoms’ for colorectal 
cancer represents further use of time as 
a diagnostic tool within primary care. The 
absence of this item for lung cancer may 
reflect the more progressive course of 
this illness. An additional crucial factor 
introduced by participants was that of 
patients’ concerns regarding risk of cancer, 
representing a patient-centred approach 
in primary care. Fear of cancer has 
been found to be prevalent in presenting 
patients21 and GPs, through a fear of 
missing a diagnosis.20 These items have not 
been previously investigated in diagnostic 
studies, possibly because they are difficult 
to measure. The inclusion of these more 
subjective indicators could again be a result 
of the make-up of the panel.
Implications for research and practice
The findings of this Delphi consensus study 
will inform a large primary care-based 
prospective cohort study (CANDID) by 
highlighting the items that clinicians feel 
are most important to include in the clinical 
assessment of primary care consulters. 
This study has also helped to highlight a 
number of potential indicators that have 
rarely been noted in the literature. Their 
importance in assessing the risk of lung 
and colorectal cancers will be tested as 
part of the CANDID study.
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